Eradication of Helicobacter Pylori: Therapies and Clinical Implications

Overview

Journal Postgrad Med J

Publisher Oxford University Press

Specialty General Medicine

Date 1992 Jul 1

PMID 1437952

Citations 8

Authors

H J OConnor

Affiliations

Soon will be listed here.

Abstract

This review presents a critical evaluation of the role of Helicobacter pylori eradication in the management of peptic ulcer disease and non-ulcer dyspepsia. On current evidence, H. pylori eradication therapy seems likely to emerge as the most rational and cost-effective treatment for duodenal ulcer. The role of H. pylori eradication in the treatment of gastric ulcer and non-ulcer dyspepsia is unclear and requires further study. The emerging problem of antibiotic resistance in H. pylori is of major clinical importance and a prime cause of treatment failure. There is increasing evidence of a link between H. pylori and gastric cancer but it is premature to recommend large-scale eradication of H. pylori as a valid strategy for the primary prevention of gastric cancer. The search continues for the ideal H. pylori eradication regimen.

Citing Articles

Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.

Buckley M, Xia H, Hyde D, Keane C, OMorain C Dig Dis Sci. 1997; 42(10):2111-5.

PMID: 9365144 DOI: 10.1023/a:1018882804607.

The presence of Helicobacter pylori in nonoperated duodenal ulcer patients compared to patients late after highly selective vagotomy.

Csendes A, Smok G, Coronel M, Avendano R, ZENTENO G, Cordova H Dig Dis Sci. 1996; 41(12):2366-8.

PMID: 9011444 DOI: 10.1007/BF02100129.

Eradication of Helicobacter pylori and long-term outcome of functional dyspepsia. A clinical endoscopic study.

Lazzaroni M, Bargiggia S, Sangaletti O, Maconi G, Boldorini M, Bianchi Porro G Dig Dis Sci. 1996; 41(8):1589-94.

PMID: 8769284 DOI: 10.1007/BF02087905.

Helicobacter pylori and gastro-oesophageal reflux disease--a prospective study.

OConnor H, Cunnane K Ir J Med Sci. 1994; 163(8):369-73.

PMID: 8002262 DOI: 10.1007/BF02942830.

Helicobacter pylori infection increases following cholecystectomy.

Caldwell M, McDermott M, Jazrawi S, ODowd G, Byrne P, Walsh T Ir J Med Sci. 1995; 164(1):52-5.

PMID: 7890538 DOI: 10.1007/BF02968117.

References

Goodwin C, Marshall B, Blincow E, Wilson D, Blackbourn S, Phillips M . Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol. 1988; 41(2):207-10. PMC: 1141380. DOI: 10.1136/jcp.41.2.207. View

Logan R, Gummett P, Misiewicz J, Karim Q, Walker M, Baron J . One week eradication regimen for Helicobacter pylori. Lancet. 1991; 338(8777):1249-52. DOI: 10.1016/0140-6736(91)92111-e. View

Patchett S, Beattie S, Leen E, Keane C, OMorain C . Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia. BMJ. 1991; 303(6812):1238-40. PMC: 1671549. DOI: 10.1136/bmj.303.6812.1238. View

Weil J, Bell G, Powell K, Morden A, Harrison G, Gant P . Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther. 1991; 5(3):309-13. DOI: 10.1111/j.1365-2036.1991.tb00032.x. View

Nomura A, STEMMERMANN G, Chyou P, Kato I, Perez-Perez G, Blaser M . Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325(16):1132-6. DOI: 10.1056/NEJM199110173251604. View

Ashton T . Cost-effectiveness of alternative medications in the treatment of duodenal ulcer. Scand J Gastroenterol. 1991; 26(1):82-8. DOI: 10.3109/00365529108996487. View

Rauws E, Tytgat G . Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990; 335(8700):1233-5. DOI: 10.1016/0140-6736(90)91301-p. View

Sitas F, Forman D, Yarnell J, Burr M, Elwood P, Pedley S . Helicobacter pylori infection rates in relation to age and social class in a population of Welsh men. Gut. 1991; 32(1):25-8. PMC: 1379208. DOI: 10.1136/gut.32.1.25. View

Forman D, Newell D, Fullerton F, Yarnell J, Stacey A, Wald N . Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302(6788):1302-5. PMC: 1670011. DOI: 10.1136/bmj.302.6788.1302. View

10.

Kang J, Tay H, Wee A, Guan R, Math M, Yap I . Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut. 1990; 31(4):476-80. PMC: 1378428. DOI: 10.1136/gut.31.4.476. View

11.

ORiordan T, Mathai E, Tobin E, McKenna D, Keane C, Sweeney E . Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut. 1990; 31(9):999-1002. PMC: 1378656. DOI: 10.1136/gut.31.9.999. View

12.

Loffeld R, Stobberingh E, Flendrig J, Arends J . Presence of Helicobacter pylori in patients with non-ulcer dyspepsia revealing normal antral histological characteristics. Digestion. 1990; 47(1):29-34. DOI: 10.1159/000200473. View

13.

Perez-Perez G, Taylor D, Bodhidatta L, Wongsrichanalai J, Baze W, Dunn B . Seroprevalence of Helicobacter pylori infections in Thailand. J Infect Dis. 1990; 161(6):1237-41. DOI: 10.1093/infdis/161.6.1237. View

14.

Loffeld R, Potters H, Stobberingh E, Flendrig J, van Spreeuwel J, Arends J . Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate. Gut. 1989; 30(9):1206-12. PMC: 1434256. DOI: 10.1136/gut.30.9.1206. View

15.

Borody T, Cole P, Noonan S, Morgan A, Lenne J, HYLAND L . Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 1989; 151(8):431-5. DOI: 10.5694/j.1326-5377.1989.tb101251.x. View

16.

Fox J, Correa P, Taylor N, Zavala D, Fontham E, Janney F . Campylobacter pylori-associated gastritis and immune response in a population at increased risk of gastric carcinoma. Am J Gastroenterol. 1989; 84(7):775-81. View

17.

Lee F, SAMLOFF I, Hardman M . Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985; 1(8441):1299-302. DOI: 10.1016/s0140-6736(85)92793-x. View

18.

Quintero Diaz M, SOTTO ESCOBAR A . Metronidazole versus cimetidine in treatment of gastroduodenal ulcer. Lancet. 1986; 1(8486):907. DOI: 10.1016/s0140-6736(86)91006-8. View

19.

Fox N, MORTON R, Jacobs J . The cost-effectiveness of maintenance therapy for duodenal ulceration with an H2-antagonist. Aliment Pharmacol Ther. 1988; 2(4):297-309. DOI: 10.1111/j.1365-2036.1988.tb00701.x. View

20.

Rokkas T, Pursey C, Uzoechina E, Dorrington L, Simmons N, FILIPE M . Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori. Gut. 1988; 29(10):1386-91. PMC: 1434011. DOI: 10.1136/gut.29.10.1386. View